↓ Skip to main content

Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in…

Overview of attention for article published in Journal of Pharmaceutical Health Care and Sciences, December 2018
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#40 of 158)
  • Above-average Attention Score compared to outputs of the same age (52nd percentile)

Mentioned by

policy
1 policy source

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
7 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)
Published in
Journal of Pharmaceutical Health Care and Sciences, December 2018
DOI 10.1186/s40780-018-0128-9
Pubmed ID
Authors

Hisanori Shimizu, Kenichi Suzuki, Takeshi Uchikura, Daiki Tsuji, Takeharu Yamanaka, Hironobu Hashimoto, Koichi Goto, Reiko Matsui, Nobuhiko Seki, Toshikazu Shimada, Shunya Ikeda, Naoki Ikegami, Toshihiro Hama, Nobuyuki Yamamoto, Tadanori Sasaki

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 7 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 7 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 29%
Student > Bachelor 1 14%
Unknown 4 57%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 2 29%
Medicine and Dentistry 1 14%
Unknown 4 57%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 July 2021.
All research outputs
#8,604,410
of 25,546,214 outputs
Outputs from Journal of Pharmaceutical Health Care and Sciences
#40
of 158 outputs
Outputs of similar age
#163,926
of 445,772 outputs
Outputs of similar age from Journal of Pharmaceutical Health Care and Sciences
#1
of 3 outputs
Altmetric has tracked 25,546,214 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 158 research outputs from this source. They receive a mean Attention Score of 3.4. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 445,772 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them